There are hundreds of thousands of knee replacement surgeries each year, and about 100,000 of them fail. But even more lead to chronic pain from misalignment or wear. In fact, 36% of people wish they had never received their surgery after the fact.
A company called Monogram (opens in new tab) is working to change that with more precise joint surgeries and custom-fitting joints, and we’re taking new investors before our intended NASDAQ listing.
Joint replacement technology hasn’t seen much innovation in the last half century.
After about 40 years of stagnancy, we believe this industry is getting a wake-up call from Monogram’s planned precision surgical robots and custom joint components that are 3D-printed to match each patient (opens in new tab).
Here’s what we believe makes the opportunity to invest in this company (opens in new tab) so unique.
Monogram’s $19.4B Joint Replacement Market The joint replacement market (opens in new tab) is projected to accelerate quickly between now and 2030, thanks to about 70 million people advancing in age.
Baby Boomers are the second-largest living adult population, so this will be a major market opportunity for Monogram, a potential first-mover in the realm of automated surgery and custom implants.
Not only is the knee replacement industry expected to expand to $26 billion by 2027 (opens in new tab), but 50% of all knee replacements are predicted to be robotic by 2030. We believe it’s only a matter of time before the word gets out and people are interested in a more precise, better-fitting joint surgery than ever before.
Monogram’s tech has 20 patents pending and the company is developing the only 3D-printed, patient-specific implants inserted with active milling robots, a great lead on the competition.
Now, the next move will put them in front of even more people.
Monogram’s Intended Public ListingMonogram’s team of experienced surgeons and engineers have already conducted demos on cadavers in front of thousands on livestream. And the team continues to perform these surgeries on cadavers in their own state-of-the-art laboratories.
Their intended NASDAQ listing (opens in new tab), planned for later this year, could give them even more publicity as a leading name in joint surgery.
But, for the time being, investors can become shareholders before Monogram stock before the planned public listing. They’re doing a Regulation A crowdfunding round where investors can get in for $7.25 a share.
Learn more about becoming a Monogram shareholder here before the opportunity ends on 5/10. (opens in new tab)
Disclosure: This is a paid advertisement for Monogram Orthopedics’ Regulation A+ offering. Learn more at invest.monogramorthopedics.com/disclaimers (opens in new tab)